Interim treatment regimens during the COVID-19 pandemic¹

NHS England has published interim treatment changes¹ to allow for greater flexibility in the management of cancer during COVID-19 pandemic to ensure clinicians have additional treatment options through this time.

It give the following recommendations regarding the management of melanoma: 

• Give oral therapy as first-line treatment for BRAF positive patients in preference to immunotherapy to reduce admission for intravenous therapy.
• Stop immunotherapy doublet (ipilimumab and nivolumab) and switch to single agent nivolumab or pembrolizumab to reduce toxicity.

Reference

1. NHS England interim treatment changes during the COVID-19 pandemic. Last updated 12 August 2020.

To download more visual summaries and complete the melanoma CPD course register to OnMedica and then click
'View full content'.